Why decision aids aren't affecting patients' decisions about prostate cancer screening... More

What happens when one low-value test leads to a "cascade" of expensive and harmful procedures? More

Social media has become the newest form of direct-to-consumer health advertising... but for what benefit? More

In a new commentary, Dr. Vinay Prasad and colleagues use a thought experiment to explain why cancer screening programs have to consider the harms as well as the benefits. More

Dr. Lisa Schwartz, expert in overdiagnosis and health care communication, passed away in November 2018. We remember her vast contribution to medicine and journalism. More

But how do we define overdiagnosis, and what makes it different from other screening harms such as false positives or overtreatment? More

American women are still getting too many mammograms. Despite recommendations from the US Preventive Services Task Force and the American Cancer Society against routine screening for breast cancer before age 50, the rates of mammogram screening have not changed significantly in the past ten years. In a recent JAMA Clinical Update, Dr. Nancy Keating and […] More

A study in The BMJ shows that overdiagnosis research is growing but discrepancies in definitions and measurement complicate the evidence. More

Not only does too much cancer screening lead to false positives and overtreatment, it can also skew our data. More

When Julie Martinez was diagnosed with thyroid cancer, she started doing research on overdiagnosis, and was shocked by what she found... More